Cancer Clinical Investigation

Medicine & Life Sciences

1. Hepatocellular Carcinoma 100%
2. Neoplasms 95%
3. Multiple Myeloma 89%
4. Survival 58%
5. Therapeutics 57%
6. Primary Myelofibrosis 50%
7. Liver 39%
8. Prostatic Neoplasms 38%
9. Liver Transplantation 37%
10. Urinary Bladder Neoplasms 33%
11. Drug Therapy 31%
12. Carcinoma 30%
13. Immunotherapy 25%
14. Polycythemia Vera 25%
15. Recurrence 23%
16. Clinical Trials 23%
17. Biomarkers 22%
18. Genes 21%
19. INCB018424 21%
20. T-Lymphocytes 20%
21. Lenalidomide 19%
22. Mutation 19%
23. Progression-Free Survival 19%
24. Dexamethasone 19%
25. Safety 18%
26. Sorafenib 18%
27. Transplants 18%
28. Radiotherapy 17%
29. Proteins 17%
30. Hematopoietic Stem Cells 17%
31. Cystectomy 17%
32. Prostatectomy 17%
33. Myelodysplastic Syndromes 17%
34. daratumumab 16%
35. Pharmaceutical Preparations 16%
36. carfilzomib 16%
37. Dendritic Cells 16%
38. Cisplatin 16%
39. Bortezomib 16%
40. Epigenomics 16%
41. Confidence Intervals 15%
42. Cholangiocarcinoma 15%
43. Robotics 15%
44. Liver Neoplasms 14%
45. Breast Neoplasms 14%
46. Fibrosis 14%
47. Bone Marrow 13%
48. Graft vs Host Disease 13%
49. Lung Neoplasms 13%
50. Phosphotransferases 13%
51. selinexor 13%
52. Stem Cells 13%
53. Acute Myeloid Leukemia 13%
54. Prostate 13%
55. Magnetic Resonance Imaging 12%
56. Head and Neck Neoplasms 12%
57. Proteogenomics 12%
58. Coronavirus 12%
59. Datasets 12%
60. Multiparametric Magnetic Resonance Imaging 12%
61. Neoplasm Metastasis 12%
62. Azacitidine 11%
63. Databases 11%
64. Mortality 11%
65. Essential Thrombocythemia 11%
66. Transplantation 11%
67. Castration 11%
68. Squamous Cell Carcinoma of Head and Neck 11%
69. Incidence 11%
70. Kidney 11%
71. Proteomics 11%
72. Ligands 10%
73. Radiation 10%
74. Non-Small Cell Lung Carcinoma 10%
75. Systematic Reviews 10%
76. ON 01910 10%
77. Gene Expression 10%
78. Meta-Analysis 10%
79. Population 10%
80. Janus Kinase Inhibitors 10%
81. Platinum 10%
82. Oropharyngeal Neoplasms 10%
83. Transcriptome 10%
84. Pandemics 10%
85. Tissue Donors 10%
86. Renal Cell Carcinoma 9%
87. Tumor Microenvironment 9%
88. Living Donors 9%
89. Muscles 9%
90. Biopsy 9%
91. Liver Diseases 9%
92. Leukemia 9%
93. Quality of Life 9%
94. Melanoma 9%
95. Nivolumab 9%
96. Thrombocytopenia 8%
97. 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 8%
98. Genome 8%
99. SARS Virus 8%
100. Growth 8%